The Frazier Life Sciences team invests in and builds companies developing and commercializing novel therapeutics.
Phathom Pharmaceuticals Announces Pricing of Initial Public Offering
Passage Bio Closes $110 Million Series B Financing
AbbVie Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma
CutisPharma Announces Acquisition of Silvergate Pharmaceuticals, Name Change to Azurity Pharmaceuticals